ORM-5029
Product Specifications
UNSPSC Description
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 can be used for study of cancer[1].
Target Antigen
Antibody-Drug Conjugates (ADCs)
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/orm-5029.html
Smiles
[R]O[M5029]
References & Citations
[1]Sara A. Hurvitz, et al. A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors. Journal of Clinical Oncology. Volume 41, Number 16_suppl. May 31, 2023.
Shipping Conditions
Dry Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-164202/ORM-5029-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-164202/ORM-5029-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
